Julie R Brahmer

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Respirology 12:320-5. 2007
  2. ncbi request reprint Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions
    Tara L Lin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G 94, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 6:251-8. 2004
  3. ncbi request reprint Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
    Julie R Brahmer
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Md Electronic address
    Semin Oncol 41:126-32. 2014
  4. pmc Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
    J R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Electronic address
    Eur J Cancer 50:302-8. 2014
  5. doi request reprint Harnessing the immune system for the treatment of non-small-cell lung cancer
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 31:1021-8. 2013
  6. pmc Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    J Thorac Oncol 6:103-8. 2011
  7. doi request reprint Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
  8. doi request reprint Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:837-45. 2010
  9. ncbi request reprint Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    Suzanne L Topalian
    Suzanne L Topalian, William H Sharfman, Julie R Brahmer, Evan J Lipson, Janis M Taube, and Drew M Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Mario Sznol and Harriet M Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT David F McDermott, Beth Israel Deaconess Medical Center Donald P Lawrence, Massachusetts General Hospital Cancer Center F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA Richard D Carvajal, Memorial Sloan Kettering Cancer Center, New York, NY Michael B Atkins, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC John D Powderly, Carolina BioOncology Institute, Huntersville, NC Philip D Leming, The Christ Hospital Cancer Center, Cincinnati, OH Igor Puzanov and Jeffrey A Sosman, Vanderbilt University Medical Center, Nashville, TN David C Smith, University of Michigan, Ann Arbor, MI and Jon M Wigginton, Georgia D Kollia, and Ashok Gupta, School of Medical Sciences
    J Clin Oncol 32:1020-30. 2014
  10. pmc Symptoms, supportive care needs, and function in cancer patients: how are they related?
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    Qual Life Res 17:665-77. 2008

Detail Information

Publications39

  1. ncbi request reprint Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Respirology 12:320-5. 2007
    ..Data are presented to support the standard use of adjuvant therapy in patients with stage II and III disease, as well as data supporting the use of neo-adjuvant therapy in selected patients with non-small cell lung cancer...
  2. ncbi request reprint Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions
    Tara L Lin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room G 94, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 6:251-8. 2004
    ..We also address the most effective and least toxic regimens for adjuvant chemotherapy and the subsets of patients likely to derive the most benefit...
  3. ncbi request reprint Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
    Julie R Brahmer
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Md Electronic address
    Semin Oncol 41:126-32. 2014
    ..Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials. ..
  4. pmc Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
    J R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Electronic address
    Eur J Cancer 50:302-8. 2014
    ....
  5. doi request reprint Harnessing the immune system for the treatment of non-small-cell lung cancer
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 31:1021-8. 2013
    ..These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer...
  6. pmc Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    J Thorac Oncol 6:103-8. 2011
    ..Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab...
  7. doi request reprint Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
    ..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management...
  8. doi request reprint Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:837-45. 2010
    ..We explored using needs assessments to identify HRQOL scores associated with patient-reported unmet needs...
  9. ncbi request reprint Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    Suzanne L Topalian
    Suzanne L Topalian, William H Sharfman, Julie R Brahmer, Evan J Lipson, Janis M Taube, and Drew M Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Mario Sznol and Harriet M Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT David F McDermott, Beth Israel Deaconess Medical Center Donald P Lawrence, Massachusetts General Hospital Cancer Center F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA Richard D Carvajal, Memorial Sloan Kettering Cancer Center, New York, NY Michael B Atkins, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC John D Powderly, Carolina BioOncology Institute, Huntersville, NC Philip D Leming, The Christ Hospital Cancer Center, Cincinnati, OH Igor Puzanov and Jeffrey A Sosman, Vanderbilt University Medical Center, Nashville, TN David C Smith, University of Michigan, Ann Arbor, MI and Jon M Wigginton, Georgia D Kollia, and Ashok Gupta, School of Medical Sciences
    J Clin Oncol 32:1020-30. 2014
    ..PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued...
  10. pmc Symptoms, supportive care needs, and function in cancer patients: how are they related?
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    Qual Life Res 17:665-77. 2008
    ..To explore the associations among symptoms, supportive care needs, and function...
  11. pmc Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    Julie R Brahmer
    Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    N Engl J Med 366:2455-65. 2012
    ..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models...
  12. ncbi request reprint Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
    ..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated...
  13. pmc Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    Evan J Lipson
    Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Clin Cancer Res 19:462-8. 2013
    ..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective...
  14. ncbi request reprint Targeting the immune system in the treatment of non-small-cell lung cancer
    Deepa Rangachari
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins Hospital, Bunting Blaustein Cancer Research Building 1, 1650 Orleans St, Room 186, Baltimore, MD, 21287, USA
    Curr Treat Options Oncol 14:580-94. 2013
    ..Given their unique antineoplastic effects, novel immune-specific clinical endpoints also are actively being investigated...
  15. doi request reprint Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
    ..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
  16. pmc Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
    Charles M Rudin
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA
    J Thorac Oncol 8:619-23. 2013
    ..On the basis of these data, we performed an exploratory clinical study, assessing the efficacy of itraconazole with cytotoxic chemotherapy in the treatment of patients with advanced lung cancer...
  17. pmc Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    N Engl J Med 366:2443-54. 2012
    ..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1...
  18. ncbi request reprint Adjuvant treatment in non-small cell lung cancer: Where are we now?
    Rosalyn A Juergens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 401 North Broadway, Johns Hopkins, Baltimore, MD 21205, USA
    J Natl Compr Canc Netw 4:595-600. 2006
    ..Cisplatin-based therapy has now been shown to provide a significant survival benefit in several trials and recent meta-analyses. These data have changed the paradigm for how early-stage lung cancer is managed...
  19. ncbi request reprint Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    Charles M Rudin
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:1119-27. 2008
    ..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib...
  20. ncbi request reprint "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?"
    Christine L Hann
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Curr Treat Options Oncol 8:28-37. 2007
    ..Prospective trials are ongoing to determine which patient and tumor characteristics are predictive of a clinical benefit from TKI therapy...
  21. ncbi request reprint Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
    Michael A Carducci
    Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 24:4092-9. 2006
    ..Secondary objectives were maximum-tolerated dose (MTD), pharmacokinetics (PK), toxicity, and response...
  22. ncbi request reprint Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future
    Rosalyn A Juergens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 2410, USA
    Curr Oncol Rep 7:248-54. 2005
    ..The goal of this paper is to review the data on adjuvant therapies that have emerged over the past 30 years, focusing specifically on the trials that have been published in the past 5 years...
  23. doi request reprint Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 17:2502-11. 2011
    ..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed...
  24. doi request reprint Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report
    Patrick M Forde
    Departments of Medical Oncology, Surgery, and Pathology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland and Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland
    J Thorac Oncol 9:414-8. 2014
    ..We report the largest series to date of 49 patients with locally advanced or metastatic pulmonary carcinoid...
  25. ncbi request reprint Update in oncology
    Julie R Brahmer
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231 1000, USA
    Ann Intern Med 143:587-92. 2005
  26. doi request reprint Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer
    Justin F Klamerus
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Lung Cancer 9:S51-6. 2008
    ..Many questions remain, such as the role of the anti-VEGF antibody in early-stage disease, the safety of bevacizumab in patients with squamous histology NSCLC, and the benefit of combination therapy in elderly patients...
  27. ncbi request reprint Second-line Therapy for advanced non-small-cell lung cancer
    Christine L Hann
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 8:243-7. 2006
    ..In 2004, two additional agents, pemetrexed and erlotinib, also received approval, giving patients three options for second-line treatment. Many promising new drugs and drug combinations are currently under investigation...
  28. doi request reprint Chemotherapy for advanced stage non-small cell lung cancer
    Amir T Fathi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Semin Thorac Cardiovasc Surg 20:210-6. 2008
    ..Clinical trials have also recently demonstrated increased efficacy for agents such as docetaxel and pemetrexed in the second line setting for refractory disease...
  29. pmc Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer
    Susanna V Ulahannan
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, Maryland, USA
    Cancer Invest 29:325-37. 2011
    ..Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC...
  30. ncbi request reprint Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice
    Claire F Snyder
    Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N Broadway, 6th Floor, Baltimore, MD 21205, USA
    Support Care Cancer 15:1075-85. 2007
    ..We investigated the item content from two health-related quality-of-life (HRQOL) questionnaires and two needs assessments for this purpose...
  31. ncbi request reprint New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer
    Patrick M Forde
    Authors Affiliation Upper Aerodigestive Malignancies Division, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    Clin Cancer Res 20:2244-8. 2014
    ..Clin Cancer Res; 20(9); 2244-8. ©2014 AACR. ..
  32. pmc Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
    Charles G Drake
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Nat Rev Clin Oncol 11:24-37. 2014
    ..In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types. ..
  33. ncbi request reprint Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care
    Malcolm V Brock
    Johns Hopkins Hospital, and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 43:47-55. 2006
    ..Lung cancer is more common in HIV-infected patients than in the general population. We examined how effectively lung cancer was being diagnosed in our HIV-infected patients...
  34. ncbi request reprint Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
    Kim A Reiss
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building I, Room 186, 401 North Broadway Street, Baltimore, MD 21287, USA
    Immunotherapy 6:459-75. 2014
    ..Future directions include optimization of drug delivery sequence and combination of immunotherapy with other therapies including cytotoxic chemotherapy, radiation, antiangiogenic agents and small-molecule tyrosine kinase inhibitors. ..
  35. ncbi request reprint New strategies in lung cancer: translating immunotherapy into clinical practice
    Patrick M Forde
    Authors Affiliation Upper Aerodigestive Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    Clin Cancer Res 20:1067-73. 2014
    ....
  36. ncbi request reprint Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
    Clin Cancer Res 9:3589-97. 2003
    ..This Phase I trial examined its toxicity and pharmacokinetics (PKs)...
  37. pmc Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  38. doi request reprint Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  39. ncbi request reprint Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry
    Alex Sparreboom
    Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Groene Hilledijk 301, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 773:183-90. 2002
    ..Our current method is approximately 60-100-fold more sensitive than previous assays, and will be used to define Tween 80 disposition in patients receiving Taxotere...